ESTRO 2021 Abstract Book

S752

ESTRO 2021

Conclusion MDT is safe and offers high local control rates in bone oligometastases of prostate cancer. At 2 years after treatment, more than 1 of 3 patients is progression-free. Prospective trials are necessary to better identify patients who benefit most from MDT. PD-0910 Radical radiotherapy in lymph node or bone metastatic prostate cancer: a single institution series C.L. deantoni 1 , A. Fodor 1 , C. Cozzarini 1 , R. Tummineri 2 , A. Sanchez Galvan 2 , S. Villa 1 , S. Baroni 1 , G. Mandurino 1 , P. Pacifico 1 , R. Castriconi 3 , C. Fiorino 3 , N.G. Di Muzio 4,1 1 IRCCS San Raffaele Scientific Institute, Department of Radiation Oncology, Milano, Italy; 2 IRCCS San Raffaele Scientific Institute, Milan, Department of Radiation Oncology, Milano, Italy; 3 IRCCS San Raffaele Scientific